Core Memory Inside The Race To Reboot Human Cells - EP 60 Nabiha Saklayen
64 snips
Mar 11, 2026 
Nabiha Saklayen, co-founder and CEO of Cellino Bio who builds automated systems for clinical-grade iPSC production. She walks through how iPSCs are reset to become any cell type. They discuss manufacturing automation, optics-based single-cell tools, surgical delivery methods, autologous versus off-the-shelf tradeoffs, costs and scaling targets, and early clinical progress in Parkinson’s and retinal/spinal trials.
AI Snips
Chapters
Transcript
Episode notes
Laser Bubble Method Gives Single Cell Precision
- Cellino's core tech grows cells on a nanofilm surface then uses focused ultrafast lasers to generate localized cavitation bubbles that remove unwanted cells.
- This surface-based bubble approach achieves single-cell precision without directly focusing the laser on each cell.
PhD Optics Work Pivoted After A Stem Cell Visit
- Nabiha pivoted her PhD ultrafast optics work toward biology after a visit to the Harvard Stem Cell Institute where hands-on IPSC methods inspired her.
- Co-founder Marina and stem cell scientist LaRod convinced her to apply laser precision to IPSC workflows.
Nebula Turns Lab Process Into A Foundry Machine
- Cellino packages the optical bioprocess into a closed cassette system called Nebula for clinical-grade manufacturing.
- Nebula fits roughly a mini-fridge and currently holds ~60 parallel cassettes per unit for bankable iPSC production.